[8]Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med,2015,373(3):232-242.

[9]Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial[J]. JAMA,2019,321(1):69-79.

[10]McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA[J]. Circulation,2019,139(3):351-361.

[11]Biessels GJ, Janssen J, van den Berg E,et al; CAROLINA? investigators. Rationale and design of the CAROLINA? - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus[J]. BMC Neurol,2018,15;18(1):7.

[12]McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of patients[J]. Diabetes Obes Metab,2015,17(11):1085-1092.

[13]Aroor AR, Sowers JR, Bender SB, et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats[J]. Endocrinolo gy,2013,154(7):2501-2513.

[14]Jax T, Stirban A, Terjung A, et al. A randomised, active- and placebocontrolled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes[J]. Cardiovasc Diabetol,2017,16(1):13.

[15]Maruhashi T, Higashi Y, Kihara Y, et al. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study[J]. Cardiovasc Diabetol,2016,15(1):134.

[16]El-Naggar AR, Zaafar D, Elyamany M, et al.The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients[J]. J Cardiovasc Pharmacol Ther,2019,24(3):254-261.

[17]von Eynatten M, Gong Y, Emser A, et al. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials[J]. Cardiovasc Diabetol,2013;12:60.

[18]Shigeta T, Aoyama M, Bando YK, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions[J]. Circulati on,2012,126(15):1838-1851.

[19]Terasaki M, Nagashima M, Nohtomi K, et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice[J]. PLoS One,2013,8(8):e.

[20]Sudo M, Li Y, Hiro T, et al. Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits[J]. Atherosclerosis,2017,265:283-291.

文章来源：《糖尿病天地(临床)》 网址: http://www.tnbtd.cn/qikandaodu/2021/0710/1463.html